Arietis

Boston, MA 02118

SBIR Award Summary

Total Number of Awards 19
Total Value of Awards $13.8MM
First Award Date 05/15/08
Most Recent Award Date 05/01/17

Key Personnel

Last Name Name Awards Contact
Dahl Thomas A Dahl 7
Coleman Kenneth Coleman 10
LAFLEUR MICHAEL LAFLEUR 2

19 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/01/17 - 04/30/18

DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis, and biofilms of indwelling devices. Many of these infections are essentially untreatable and lead to substantial morbidity and mortality. In many...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 03/01/17 - 02/28/18

? DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic against vancomycin resistant enterococcus (VRE). These infections are a serious health concern because antibiotic resistance has gotten to the point where there are few or no effective treatment options available. For the enterococci, resistance is inhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/01/16 - 04/30/17

DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis, and biofilms of indwelling devices. Many of these infections are essentially untreatable and lead to substantial morbidity and mortality. In many...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 03/15/16 - 02/28/17

? DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic against vancomycin resistant enterococcus (VRE). These infections are a serious health concern because antibiotic resistance has gotten to the point where there are few or no effective treatment options available. For the enterococci, resistance is inhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/15 - 06/30/16

DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 500,000 cases annually of active infection in the US. The currently-used ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis, and biofilms of indwelling devices. Many of these infections are essentially untreatable and lead to substantial morbidity and mortality. In many...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 500,000 cases annually of active infection in the US. The currently-used ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/15/14 - 04/30/15

DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis, and biofilms of indwelling devices. Many of these infections are essentially untreatable and lead to substantial morbidity and mortality. In many...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 500,000 cases annually of active infection in the US. The currently-used ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 1.5 million cases annually of active infection in the US. The currently...

Load More